摘要
目的研究血清鳞状细胞癌抗原(SCC-Ag)、细胞角蛋白19(CYFRA21-1)、神经元特异性烯醇化酶(NSE)、癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原199(CA199)水平在非小细胞肺癌诊治中的价值。方法选取80例非小细胞肺癌患者(观察组)和80名健康体检者(对照组)作为研究对象,检测并比较两组的SCC-Ag、CYFRA21-1、NSE、CEA、CA125、CA199水平,分析其联合诊断的价值。结果观察组的SCC-Ag、CYFRA21-1、NSE、CEA、CA125、CA199水平均高于对照组(P<0.05)。观察组中腺癌患者和鳞癌患者的SCC-Ag、CYFRA21-1、NSE、CEA、CA199水平有显著差异(P<0.05)。SCC-Ag、CYFRA21-1、NSE、CEA、CA125、CA199联合诊断的阳性率高于单一诊断(P<0.05)。治疗后,观察组的SCC-Ag、CYFRA21-1、NSE、CEA、CA125、CA199水平均低于治疗前(P<0.05)。结论SCC-Ag、CYFRA21-1、NSE、CEA、CA125、CA199水平联合检测在非小细胞肺癌诊治中的应用价值显著,能早期明确疾病,为患者后期治疗提供依据。
Objective To study the value of serum squamous cell carcinoma antigen(SCC-Ag),cytokeratin 19(CYFRA21-1),neuron-specific enolase(NSE),carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)and carbohydrate antigen 199(CA199)levels in the diagnosis and treatment of non-small cell lung cancer.Methods Eighty patients with non-small cell lung cancer(observation group)and 80 healthy people(control group)were selected as the research objects.The levels of SCC-Ag,CYFRA21-1,NSE,CEA,CA125 and CA199 in the two groups were detected and compared,and the value of their combined diagnosis was analyzed.Results The levels of SCC-Ag,CYFRA21-1,NSE,CEA,CA125 and CA199 in the observation group were higher than those in the control group(P<0.05).There were significant differences in the levels of SCC-Ag,CYFRA21-1,NSE,CEA,CA125 and CA199 between adenocarcinoma patients and squamous cell carcinoma patients in the observation group(P<0.05).The positive rate of combined diagnosis of SCC-Ag,CYFRA21-1,NSE,CEA,CA125,CA199 were higher than those of single diagnosis(P<0.05).After treatment,the levels of SCC-Ag,CYFRA21-1,NSE,CEA,CA125 and CA199 in the observation group were lower than those before treatment(P<0.05).Conclusion The combined detection of SCC-Ag,CYFRA21-1,NSE,CEA,CA125 and CA199 levels has significant application value in the diagnosis and treatment of non-small cell lung cancer,which can identify the disease in the early stage and provide basis for the later treatment of patients.
作者
陈涛
CHEN Tao(Clinical Laboratory Department,Anyang Tumor Hospital,Anyang 455000,China)
出处
《临床医学研究与实践》
2021年第12期39-40,53,共3页
Clinical Research and Practice